Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis.

Creticos PS, Esch RE, Couroux P, Gentile D, D'Angelo P, Whitlow B, Alexander M, Coyne TC.

J Allergy Clin Immunol. 2014 Mar;133(3):751-8. doi: 10.1016/j.jaci.2013.10.041. Epub 2013 Dec 12. Erratum in: J Allergy Clin Immunol. 2014 May;133(5):1502.

PMID:
24332263
2.

Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.

Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE.

J Allergy Clin Immunol. 2010 Mar;125(3):660-6, 666.e1-666.e4. doi: 10.1016/j.jaci.2009.12.931. Epub 2010 Feb 11.

PMID:
20153030
3.

Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.

Bowen T, Greenbaum J, Charbonneau Y, Hebert J, Filderman R, Sussman G, Del Carpio J, Gold M, Keith P, Moote W, Cecchetto S, Cecchetto O, Sharp D, Broutin O, André C.

Ann Allergy Asthma Immunol. 2004 Nov;93(5):425-30.

PMID:
15562880
4.

Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis.

Kim H, Waserman S, Hébert J, Blaiss M, Nelson H, Creticos P, Kaur A, Maloney J, Li Z, Nolte H.

Allergy Asthma Clin Immunol. 2014 Nov 10;10(1):55. doi: 10.1186/1710-1492-10-55. eCollection 2014.

5.

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults.

Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nékám K, Nolte H.

J Allergy Clin Immunol. 2013 May;131(5):1342-9.e6. doi: 10.1016/j.jaci.2013.03.019.

PMID:
23622121
6.

Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.

Nolte H, Hébert J, Berman G, Gawchik S, White M, Kaur A, Liu N, Lumry W, Maloney J.

Ann Allergy Asthma Immunol. 2013 Jun;110(6):450-456.e4. doi: 10.1016/j.anai.2013.03.013. Epub 2013 May 2.

PMID:
23706715
7.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.

Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B.

J Allergy Clin Immunol. 2014 Jan;133(1):121-9.e1-2. doi: 10.1016/j.jaci.2013.05.032. Epub 2013 Jul 16.

PMID:
23870670
8.
9.

Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis.

Nayak AS, Atiee GJ, Dige E, Maloney J, Nolte H.

Allergy Asthma Proc. 2012 Sep-Oct;33(5):404-10. doi: 10.2500/aap.2012.33.3605. Erratum in: Allergy Asthma Proc. 2012 Nov-Dec;33(6):499.

PMID:
23026182
10.

Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.

Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W.

Clin Ther. 2011 Jul;33(7):828-40. doi: 10.1016/j.clinthera.2011.06.006. Epub 2011 Jul 7.

PMID:
21741092
11.

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.

Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S.

J Allergy Clin Immunol. 2006 Apr;117(4):802-9.

PMID:
16630937
13.

Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.

Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, Barlan IB.

Respir Med. 2013 Sep;107(9):1322-9. doi: 10.1016/j.rmed.2013.06.021. Epub 2013 Jul 23.

14.

Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.

Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H.

Ann Allergy Asthma Immunol. 2014 Feb;112(2):146-153.e2. doi: 10.1016/j.anai.2013.11.018. Epub 2013 Dec 21.

PMID:
24468255
15.

Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study.

Leynadier F, Banoun L, Dollois B, Terrier P, Epstein M, Guinnepain MT, Firon D, Traube C, Fadel R, André C.

Clin Exp Allergy. 2001 Jul;31(7):988-96.

PMID:
11467988
16.

Safety and tolerability of a short ragweed sublingual immunotherapy tablet.

Nolte H, Amar N, Bernstein DI, Lanier BQ, Creticos P, Berman G, Kaur A, Hébert J, Maloney J.

Ann Allergy Asthma Immunol. 2014 Jul;113(1):93-100.e3. doi: 10.1016/j.anai.2014.04.018. Epub 2014 May 14.

PMID:
24836393
17.

Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.

Nelson H, Lehmann L, Blaiss MS.

Curr Med Res Opin. 2012 Jun;28(6):1043-51. doi: 10.1185/03007995.2012.684676. Epub 2012 May 9. Review.

PMID:
22502864
18.

Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.

Wessel F, Chartier A, Meunier JP, Magnan A.

Clin Drug Investig. 2012 Jul 1;32(7):451-63. doi: 10.2165/11634270-000000000-00000.

PMID:
22594491
19.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.

Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F.

J Allergy Clin Immunol. 2009 Jan;123(1):167-173.e7. doi: 10.1016/j.jaci.2008.10.044.

PMID:
19130937
20.

Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review.

Chelladurai Y, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, Lin SY.

J Allergy Clin Immunol Pract. 2013 Jul-Aug;1(4):361-9. doi: 10.1016/j.jaip.2013.04.005. Epub 2013 Jun 4. Review.

PMID:
24565541
Items per page

Supplemental Content

Write to the Help Desk